Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Biogen (BIIB)

Biogen expects $46 million acquired R&D charge, cutting Q2 2025 EPS by $0.26

Negative Impact 3 of 5 earnings Written later

Biogen said its preliminary second-quarter 2025 GAAP and non-GAAP results will include about $46 million in pre-tax acquired in-process R&D, upfront and milestone expense. That charge is expected to reduce diluted earnings per share by about $0.26. Biogen also said the quarter's results have not been finalized and could differ from these estimates.

Key points

  • Estimated pre-tax acquired in-process R&D, upfront and milestone expense: about $46 million for the quarter ended June 30, 2025
  • Expected impact on GAAP and non-GAAP diluted EPS: about ($0.26) per share
  • Biogen does not forecast this expense because the timing and size of such deals are uncertain; Q2 results remain subject to closing procedures

The filing

CompanyBiogen (BIIB)
Form8-K, current report
Filed with the SECJul 7, 2025, 4:10 PM ET
Accession number0000875045-25-000027

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.